These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26226846)

  • 41. The utility of immunohistochemical testing for mismatch repair proteins in fine needle aspiration specimens of pancreatic adenocarcinoma.
    Mettman D; Haer E; Olyaee M; Rastogi A; Madan R; O'Neil M; Kelting S; Dennis K; Fan F
    Ann Diagn Pathol; 2020 Aug; 47():151552. PubMed ID: 32570025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
    Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant chemotherapy in elderly patients with pancreatic cancer.
    Nagrial AM; Chang DK; Nguyen NQ; Johns AL; Chantrill LA; Humphris JL; Chin VT; Samra JS; Gill AJ; Pajic M; ; Pinese M; Colvin EK; Scarlett CJ; Chou A; Kench JG; Sutherland RL; Horvath LG; Biankin AV
    Br J Cancer; 2014 Jan; 110(2):313-9. PubMed ID: 24263063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population.
    Sini MC; Doro MG; Frogheri L; Zinellu A; Paliogiannis P; Porcu A; Scognamillo F; Delogu D; Santeufemia DA; Persico I; Palomba G; Maestrale GB; Cossu A; Palmieri G
    J Transl Med; 2024 Jan; 22(1):108. PubMed ID: 38280995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma.
    Heby M; Lundgren S; Nodin B; Elebro J; Eberhard J; Jirström K
    J Transl Med; 2018 Mar; 16(1):66. PubMed ID: 29540182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.
    Dong X; Jiao L; Li Y; Evans DB; Wang H; Hess KR; Abbruzzese JL; Li D
    J Clin Oncol; 2009 Apr; 27(10):1592-9. PubMed ID: 19237629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
    Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
    Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy.
    Kieler M; Unseld M; Wojta J; Kaider A; Bianconi D; Demyanets S; Prager GW
    Med Oncol; 2018 Nov; 36(1):1. PubMed ID: 30426271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
    Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
    Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
    BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma.
    Cloyd JM; Katz MHG; Wang H; Cuddy A; You YN
    JAMA Surg; 2017 Nov; 152(11):1086-1088. PubMed ID: 28793134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinicopathologic characteristics of resectable colorectal cancer with mismatch repair protein defects in Chinese population: Retrospective case series and literature review.
    Li J; Xu Q; Luo C; Chen L; Ying J
    Medicine (Baltimore); 2020 Jun; 99(24):e20554. PubMed ID: 32541478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
    N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different?
    Luchini C; Grant RC; Scarpa A; Gallinger S
    Gut; 2021 Oct; 70(10):1809-1811. PubMed ID: 33468535
    [No Abstract]   [Full Text] [Related]  

  • 60. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.